Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
|Videos|March 13, 2017
Next Steps for Treatment of Ovarian Cancer
Author(s)Elizabeth Swisher, MD
Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer. Combinations of PARP inhibitors with other DNA repair agents or even with immunotherapy has started to interest researchers.
Advertisement
Advertisement
Related to this article
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
5